1. Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH. Issue 4 (4th January 2021) Authors: Harrison, Stephen A.; Bashir, Mustafa; Moussa, Sam E.; McCarty, Kevin; Pablo Frias, Juan; Taub, Rebecca; Alkhouri, Naim Journal: Hepatology communications Issue: Volume 5:Issue 4(2021) Page Start: 573 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Impact of lixisenatide dose range on clinical outcomes with fixed-ratio combination iGlarLixi in patients with type 2 diabetes. (3rd April 2019) Authors: Pablo Frias, Juan; Lorenz, Martin; Roberts, Michelle; Dex, Terry; Schmider, Wolfgang; Hurst, William; Skolnik, Neil Journal: Current medical research and opinion Issue: Volume 35:Number 4(2019) Page Start: 689 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Pegbelfermin (BMS‐986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study. Issue 1 (6th December 2018) Authors: Charles, Edgar D.; Neuschwander‐Tetri, Brent A.; Pablo Frias, Juan; Kundu, Sudeep; Luo, Yi; Tirucherai, Giridhar S.; Christian, Rose Journal: Obesity Issue: Volume 27:Issue 1(2019) Page Start: 41 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗